Table 1. Disease characteristics Patient... | American Society of Hematology

Table 1.

Disease characteristics

Patient no.	MDS category			% marrow blasts	NF-κB level^*	Flow score
Patient no.		FAB	WHO	% marrow blasts	NF-κB level^*	Flow score
1	RA	RA	2	0.6	1
2	RA	RCMD	4	1.4	2
3	RA	RCMD	4	0.9	0
4	RA	5q-	4	11.0	2
5	RA	5q-	2	2.4	0
6	RA	5q-	4	1.6	0
7	RA	5q-	3	3.1	1
8	RA	RA	3	1.5	4
9	RA	RCMD	4	1.5	2
10	RARS	RARS	4	1.3	1
11	RARS	RARS	2	6.4	2
12	RARS	RCMD-RS	4	5.9	3
13	RAEB	RAEB1	6	19.0	5
14	RAEB	RAEB1	6	6.79	3
15	RAEB	RAEB1	8	5.6	2
16	RAEB	RAEB2	13	11.0	6
17	RAEB	RAEB2	11	5.86	5
18	RAEB	RAEB2	18	5.6	6
19	RAEB	RAEB2	12	3.8	5
20	RAEB	RAEB2	17	7.0	6
21	RAEB-T	tAML	29	6.78	6
22	CMML	CMML1	5	0.3	2
23	CMML	CMML2	10	3.1	4
24	CMML	CMML1	1	1.0	NA
25	CMML	CMML2	10	4.2	3

Patient no.	MDS category			% marrow blasts	NF-κB level^*	Flow score
Patient no.		FAB	WHO	% marrow blasts	NF-κB level^*	Flow score
1	RA	RA	2	0.6	1
2	RA	RCMD	4	1.4	2
3	RA	RCMD	4	0.9	0
4	RA	5q-	4	11.0	2
5	RA	5q-	2	2.4	0
6	RA	5q-	4	1.6	0
7	RA	5q-	3	3.1	1
8	RA	RA	3	1.5	4
9	RA	RCMD	4	1.5	2
10	RARS	RARS	4	1.3	1
11	RARS	RARS	2	6.4	2
12	RARS	RCMD-RS	4	5.9	3
13	RAEB	RAEB1	6	19.0	5
14	RAEB	RAEB1	6	6.79	3
15	RAEB	RAEB1	8	5.6	2
16	RAEB	RAEB2	13	11.0	6
17	RAEB	RAEB2	11	5.86	5
18	RAEB	RAEB2	18	5.6	6
19	RAEB	RAEB2	12	3.8	5
20	RAEB	RAEB2	17	7.0	6
21	RAEB-T	tAML	29	6.78	6
22	CMML	CMML1	5	0.3	2
23	CMML	CMML2	10	3.1	4
24	CMML	CMML1	1	1.0	NA
25	CMML	CMML2	10	4.2	3

The flow score considers phenotypic aberrancies as determined by 16 monoclonal anti–myeloid/monocyte antibodies, scatter properties, myeloid to lymphoid ratio of marrow cells, and blast count. The score has been shown to add prognostic information beyond that provided by the International Prognostic Scoring System, and in transplanted patients to correlate with posttransplantation relapse.³⁴

FAB indicates French-American-British classification; WHO, World Health Organization; RA, refractory anemia; RCMD, refractory cytopenia with multilineage dysplasia; RARS, RA with ringed sideroblasts; RCMD-RS, RMCD with ringed sideroblasts; RAEB, RA with excess of blasts; RAEB-T, RAEB in transformation; CMML, chronic myelomonocytic leukemia; and tAML, transformed acute myeloid leukemia. NA indicates not available.

NF-κB activity in bone marrow mononuclear cells; nuclear extracts were prepared as described in “Materials and methods” and electrophoretic mobility shift assays were carried out. Protein binding levels were determined by densitometry using ImageQuant software. Results represent intensity ratios of patient samples against normal. Results are illustrated graphically in Figure 1. Levels in RAEB were statistically significantly higher than in RA/RARS (P = .008)

View Large

This Feature Is Available To Subscribers Only